Orion Corp
KRX:271560
Orion Corp
Income from Continuing Operations
Orion Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orion Corp
KRX:271560
|
Income from Continuing Operations
₩533.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
CJ CheilJedang Corp
KRX:097950
|
Income from Continuing Operations
₩361.8B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Ottogi Corp
KRX:007310
|
Income from Continuing Operations
₩137.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
S
|
Samyang Foods Co Ltd
KRX:003230
|
Income from Continuing Operations
₩271.3B
|
CAGR 3-Years
69%
|
CAGR 5-Years
35%
|
CAGR 10-Years
52%
|
|
|
Dongwon Industries Co Ltd
KRX:006040
|
Income from Continuing Operations
₩113.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
7%
|
|
|
Nongshim Co Ltd
KRX:004370
|
Income from Continuing Operations
₩157.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
What is Orion Corp's Income from Continuing Operations?
Income from Continuing Operations
533.2B
KRW
Based on the financial report for Dec 31, 2024, Orion Corp's Income from Continuing Operations amounts to 533.2B KRW.
What is Orion Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
19%
Over the last year, the Income from Continuing Operations growth was 39%. The average annual Income from Continuing Operations growth rates for Orion Corp have been 26% over the past three years , 19% over the past five years .
You don't have any saved screeners yet